Contract development and manufacturing organisation (CDMO) Recipharm, has entered into a long term agreement with Sato Pharmaceutical for the commercial manufacture and delivery of Emla Patch to Japan.
Tokyo-based OTC company, Sato, will launch the Emla Patch, a local anaesthetic product. Recipharm’s facility in Karlskoga, Sweden, will produce and deliver to Sato.
After a successful launch in Japan, it is expected that the annual volumes of Emla Patch to Sato will be a significant addition to the present production at the Karlskoga facility.
Ingela Palmkvist, General Manager at Recipharm in Karlskoga said: “We first established a business relationship with Sato in 2012 and this new supply agreement extends our partnership further.”